What does this study add?

• In both studies, a greater proportion treated with lebrikizumab Q2W (75.8%; 64.6%) and Q4W (74.2%; 80.6%) maintained IGA 0/1 with at least 2-point improvement versus the placebo withdrawal arm (46.5%; 49.8%).
• At Week 52, EASI75 was maintained by 79.2% and 77.4% on lebrikizumab Q2W, 79.2% and 84.7% on Q4W dosing, and 61.3% and 72.0% of patients in the withdrawal arm.
• 81.2% and 90.3% of patients on Q2W dosing maintained at least 4-point improvement from baseline in pruritus, versus 80.4% and 88.1% of patients on Q4W, and 65.4% and 67.6% on placebo.
• Across treatment arms, the proportions using rescue therapy were 14.0% and 16.4% in ADvocate-1 and -2, respectively.
• Overall, 58.1% and 68.1% of lebrikizumab patients reported a treatment-emergent adverse event in ADvocate-1 and -2, respectively; most were mild or moderate in severity.
• Serious adverse events were reported by 3.3% and 2.6% of ADvocate-1 and -2 patients; none were assessed as related to study drug.
• In ADvocate-1 and -2, 2.3% and 3.8% of patients reported an adverse event leading to treatment discontinuation, respectively.